Evidence map›Paper›PMID 37284895›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2023

PSMA-617 inhibits proliferation and potentiates the

Yi Zhao, Juraj Culman, Ingolf Cascorbi, Niklas Nithack, Marlies Marx, Maaz Zuhayra, Ulf Lützen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Exploring the Therapeutic Potential ofInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yi ZhaoDepartment of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. Yi.Zhao@uksh.de.
Juraj CulmanInstitute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Ingolf CascorbiInstitute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Niklas NithackCentral Rhine Community Hospital-Clinic for Urology and Pediatric Urology, Koblenz, Germany.
Marlies MarxDepartment of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Maaz ZuhayraDepartment of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Ulf LützenDepartment of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
University Hospital Schleswig-Holstein · DEUniversity of Lübeck · DEBundeswehrzentralkrankenhaus Koblenz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human prostate-specific membrane antigen (PSMA) is substantially up-regulated in metastatic prostate cancer (PCa) cells. PSMA can be targeted by

Indexed as

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingHumansLutetiumMaleProstate-Specific AntigenDipeptidesHeterocyclic Compounds, 1-RingLutetiumPluvictoProstate-Specific AntigenPSMA-617177Lu-PSMA-617Anti-proliferationCell deathProstate carcinoma cellsPSMA-617

Identifiers

PMID37284895
PMCPMC10567812
OpenAlexW4379599497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.